MoonLake Immunotherapeutics (MLTX) Accumulated Expenses (2020 - 2026)

MoonLake Immunotherapeutics' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $21.8 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 106.91% year-over-year to $21.8 million; the TTM figure through Mar 2026 stood at $21.8 million (up 106.91% YoY), while the FY2025 annual figure was $14.7 million, up 21.42% from the prior year.
• Accumulated Expenses was $21.8 million for Q1 2026 at MoonLake Immunotherapeutics, up from $14.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $21.8 million in Q1 2026 to a low of $30000.0 in Q1 2022.
• Historically, Accumulated Expenses has averaged $8.4 million across 5 years, with a median of $6.9 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses sank 50.0% in 2022, then soared 10889.46% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $7.3 million in 2022, then slipped by 4.5% to $6.9 million in 2023, then jumped by 74.59% to $12.1 million in 2024, then climbed by 21.42% to $14.7 million in 2025, then jumped by 48.49% to $21.8 million in 2026.
• The last three Accumulated Expenses figures came in at $21.8 million (Q1 2026), $14.7 million (Q4 2025), and $21.6 million (Q3 2025), per Business Quant data.